<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20220110053683N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-04-05</date_registration>
      <primary_sponsor>Vice Chancellor for Research and Technology of Arak University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of the effect of olive oil and sesame oil on prevention of pressure ulcer</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the effect of olive oil and sesame oil on the prevention of pressure ulcers in ICU patients.</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-04-09</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>60</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/61205</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Triple blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: In simple random sampling, each element of the target community has an equal chance of being selected.
In this method, the required persons or objects are randomly selected from the list of statistical population that has been numbered and prepared for this purpose.
In our study, the random number table method will be used and we will move from right to left horizontally. We will place odd numbers in intervention group 1 and even numbers in intervention group 2, then start by entering each of the samples with the conditions for inclusion in the study, Blinding description: In this study, the  nurse - the person analyzing the statistical data - the patient himself will be blinded.
To blind the nurse, two groups of glass containers (a - b) of the same color are used for which olive and sesame oil are inseparable. Also, sesame and odorless olive oil made by Barij Essential Oil Company are used.
To blind the person analyzing the statistical data, the information of the two groups with the symbols A and B, without mentioning which type of oil was used in each group, will be provided to the statistical data analyzer.
In order to blind patients, the necessary explanations will be given at the beginning of the research (In this research, two types of oils are used and you will be randomly placed in one of these two groups without knowing it).</study_design>
      <phase>2</phase>
      <hc_freetext>Pressure ulcer.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group 1: Admission will be assessed with Braden instrument, and those with a score below 14 who are at moderate to severe risk of bed sore will be included in the study. Then, on a daily basis, pressure ulcer prevention methods, such as changing position at least every two hours, using small pillows between the legs or heels to remove and reduce pressure, controlling urinary incontinence, and using absorbent pads and cleansing the skin Infection) is routinely performed for patients. The researcher first tests some sesame oil on the inner area of the forearm and if there is no allergic reaction, in the next steps twice a day (9-21 hours), 2-3 cc on pressure points (hip, sacrum, heel) is rubbed and allowed 1-2 minutes to absorb for 7 days. Then the sacrum’ hip and heel of both groups of patients will be assessed on days 3 and 7 (based on previous studies as a cut point) in terms of incidence of pressure ulcer. Intervention 2: Intervention group 2: Admission will be assessed with Braden instrument, and those with a score below 14 who are at moderate to severe risk of bed sore will be included in the study. Then, on a daily basis, pressure ulcer prevention methods, such as changing position at least every two hours, using small pillows between the legs or heels to remove and reduce pressure, controlling urinary incontinence, and using absorbent pads and cleansing the skin Infection) is routinely performed for patients. The researcher first tests some olive oil on the inner area of the forearm and if there is no allergic reaction, in the next steps twice a day (9-21 hours), 2-3 cc on pressure points (hip, sacrum, heel) is rubbed and allowed 1-2 minutes to absorb for 7 days. Then the sacrum’ hip and heel of both groups of patients will be assessed on days 3 and 7 (based on previous studies as a cut point) in terms of incidence of pressure ulcer.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no more information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Parsa Ahmadi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 54, Dokhaniat town, Daneshgah town, Saqqez</address>
        <city>Arak</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6681473677</zip>
        <telephone>+98 87 3631 3922</telephone>
        <email>parsawe@gmail.com</email>
        <affiliation>Arak University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>fatemeh mehrabi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>University Complex of the Great Prophet. sardasht .  Arak</address>
        <city>arak</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>٣٨١٩٦٩٣٣٤٥</zip>
        <telephone>+98 86 3417 3505</telephone>
        <email>fmehrabi1392@gmail.com</email>
        <affiliation>Arak University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Willingness to participate in research
Age over 18 years and under 65 years
Patients who are at moderate to severe risk of bed sores and score less than 14 according to the nurse's diagnosis and based on the scaling of the removal tool
Probability of continuing hospitalization in the ICU
Less than 24 hours have passed since their admission to the ICU and they have not been admitted to another ward before
Having a systolic blood pressure of 10 mm Hg and above
Have a hemoglobin of 12 or higher.</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>have Skin diseases (such as psoriasis, fungal infections, fleas and ticks)
Having a pressure sore at the time of admission
Systemic diseases such as diabetes, bleeding from the site of injury, heart failure, kidney failure and advanced stage cancer
Receiving vasoactive drugs
Having a fever (body temperature above 38.8)</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>L89</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Pressure ulcer</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Prevention</i_code>
      <i_code>Prevention</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group 1: Admission will be assessed with Braden instrument, and those with a score below 14 who are at moderate to severe risk of bed sore will be included in the study. Then, on a daily basis, pressure ulcer prevention methods, such as changing position at least every two hours, using small pillows between the legs or heels to remove and reduce pressure, controlling urinary incontinence, and using absorbent pads and cleansing the skin Infection) is routinely performed for patients. The researcher first tests some sesame oil on the inner area of the forearm and if there is no allergic reaction, in the next steps twice a day (9-21 hours), 2-3 cc on pressure points (hip, sacrum, heel) is rubbed and allowed 1-2 minutes to absorb for 7 days. Then the sacrum’ hip and heel of both groups of patients will be assessed on days 3 and 7 (based on previous studies as a cut point) in terms of incidence of pressure ulcer.</i_keyword>
      <i_keyword>Intervention group 2: Admission will be assessed with Braden instrument, and those with a score below 14 who are at moderate to severe risk of bed sore will be included in the study. Then, on a daily basis, pressure ulcer prevention methods, such as changing position at least every two hours, using small pillows between the legs or heels to remove and reduce pressure, controlling urinary incontinence, and using absorbent pads and cleansing the skin Infection) is routinely performed for patients. The researcher first tests some olive oil on the inner area of the forearm and if there is no allergic reaction, in the next steps twice a day (9-21 hours), 2-3 cc on pressure points (hip, sacrum, heel) is rubbed and allowed 1-2 minutes to absorb for 7 days. Then the sacrum’ hip and heel of both groups of patients will be assessed on days 3 and 7 (based on previous studies as a cut point) in terms of incidence of pressure ulcer.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Prevention of pressure ulcers. Timepoint: at the start of reasrch and day 3 - 7. Method of measurement: Braden score.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Vice Chancellor for Research and Technology of Arak University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-03-06</approval_date>
        <contact_name>Ethics committee of Arak University of Medical Sciences</contact_name>
        <contact_address>second partition, second floor , Vice Chancellor for Research and Technology، Arak University of Medical Sciences and Health Services, Payambar Azam (PBUH) University Complex, around Dr. Mehdi Charm Dooz Square, Dr. Mohammad Gharib Blvd, Sardasht region, Arak, Markazi Arak Markazi Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
